Bimagrumab vs Enobosarm

Bimagrumab (A-tier) vs Enobosarm (D-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

Bimagrumab · tier A

Bimagrumab is an investigational activin type II receptor antibody with randomized intravenous evidence for reducing body weight and fat mass while preserving or increasing lean mass. FDA's July 2026 Purple Book data snapshot had no bimagrumab or listed development-identifier entry when checked on August 15, 2026.

BELIEVE showed direct 48-week weight and body-composition effects in 507 adults without diabetes. The trial was completed and published, but it does not supply approval, cardiovascular-outcome, mortality, function, or post-treatment durability evidence.

507 adults in the completed BELIEVE trial · half-life not stated as a universal value; the cited older-adult study supports target-mediated disposition and about 40% SC bioavailability · weight loss

Enobosarm · tier D

Enobosarm, also called ostarine or GTx-024, is an unapproved androgen-receptor SARM with short lean-mass signals and split registry-posted phase 3 lean-mass and function results.

Short randomized trials found lean-mass changes in selected older and cancer populations. POWER1 and POWER2 posted split lean-mass and stair-power responder patterns, and the record does not establish durable function, survival, athletic benefit, or long-term safety.

159 / 100 randomized and efficacy-evaluable phase 2 denominators · half-life not stated; no complete source-backed base PK set in the cited public outcome record · androgens

at a glance

• Bimagrumab: tier A · 507 adults in the completed BELIEVE trial
• Enobosarm: tier D · 159 / 100 randomized and efficacy-evaluable phase 2 denominators

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.